Why Selection of a Contract Manufacturing Organization (CMO) for HPAPI Development is Necessary? Highly potent active pharmaceutical ingredients (HPAPIs) are the compounds used extensively today for the treatment of respiratory disorders, cancer and hormonal imbalances. The key factors driving the demand for highly potent active pharmaceutical ingredients (HPAPIs) are the rise in the oncology therapeutics market as well as the surge in the need for better medicines for treating Cardiovascular, Central Nervous System, Hormonal, Eye, Infectious, Metabolic and Inflammatory diseases. How to Select the Right CMO for Large Scale Production of HPAPIs? Choose a globally recognized CMO that focuses on developing HPAPIs through a state-of-the-art facility better known as global HPAPI CMOs. Companies like Roche & Genentech are known for their best in class processes for CMO selection and management. They identify challenges in managing a potent CMO supply chain and propose best practice guidelines for processing highly potent APIs. Check for the description of processes, scale up conditions and drug load (in the case of DP) which can impact suitability. Highly potent molecules need to be reviewed and evaluated against existing equipment and facility audits before they are placed at the site. Across all three API manufacturing categories, buyers of CMO services iterated that roughly one-quarter (26 percent) of outsourced projects are allocated to strategic partners. Despite expressed interest in forming strategic partnerships, the bulk of projects are still allocated to tactical service providers (37 percent to 40 percent), followed by preferred vendors (34 percent to 37 percent). Interestingly, respondents showed higher levels of interest in forming strategic partnerships with high-potency API and biologics manufacturers than they did with small-molecule manufacturers (36 percent and 35 percent very interested as compared to 25 percent, respectively). There can be some correlation between a buyer’s interest level in a strategic partnership with an API manufacturer or a biological Highly Potent API manufacturer (HPAPI CMO) and the likelihood that a tactical provider would advance from tactical to preferred provider and then strategic partner. Just as a higher percentage of respondents were interested in forming strategic partnerships with high potency and biologics API manufacturers, these types of HPAPI CMOs were more likely to move up the ranks in outsourcing relationships. HPAPI manufacturers (HPAPIs CMOs) had the greatest probability of moving from a tactical provider to a strategic partner, with 81 percent stating it is likely a tactical HPAPI CMO will advance to a preferred provider, and 84 percent stating it is likely a preferred provider of HPAPI will become a strategic partner. As interest levels in forming strategic partnerships varied by the type of API manufacturing outsourced, it makes sense that the fundamental attributes that influence CMO selection varied somewhat as well. The attributes that are quantifiable or measurable in nature, such as geographic location or manufacturing capacity, fall under the umbrella of “hard traits.” These attributes are not easily changed, nor can they be quickly changed in order to win a project. The top three hard traits that sponsors desire in a small molecule API manufacturer are improved quality/regulatory positioning, experience, and timeliness. For HPAPI manufacturers or HPAPI CMOs, experience takes the top position, followed by timeliness and the CMO’s financial stability. Sponsors looking to engage a HPAPI CMO for biologics manufacturing prioritize experience, followed by improved quality/ regulatory positioning and, in third position, timeliness. In the research, respondents are also asked about soft traits that influence CMO choice. Soft traits describe the less quantifiable characteristics that one can’t necessarily provide a set of measures to assess; rather they are the attributes that relay the dynamic of the working relationship. Similar to the hard traits, there is overlap across the group, but slightly different prioritization of qualities. Good communication and an understanding of the customer’s requirements were prioritized in the top three across all three API categories. High-potency and biologics outsourcers placed good communication first and understanding of the customer’s requirements third, whereas small-molecule outsourcers placed understanding of the customer’s requirements first and good communication second. A “willingness to go the extra mile” prioritized in the top-three soft traits for both small-molecule and biologics outsourcers (third and second positions, respectively), while high-potency buyers valued a company’s reputation (ranked second) over willingness to go the extra mile. It is vital that HPAPI-handling systems and equipment are tested and verified to meet the necessary isolation requirements. For example, isolation equipment may be expected to meet a containment capability of less than 1 ?g/m3. The capability of equipment, systems, and procedures to contain and isolate materials under expected operating conditions must be verified in a High Potency lab as a critical component of the overall HPAPI-handling program. This process typically requires the use of both air and surface industrial hygiene sampling methods to confirm proper isolation following a detailed sampling plan. In many cases, sampling and testing methods for products in early preclinical or clinical testing have not been developed. Therefore, surrogate products such as lactose or naproxen sodium, are frequently used to complete the equipment testing. It is believed that a promising pipeline of targeted therapeutic drugs will help the HPAPI market progress in the coming years. HPAPI drugs have minimal side effects and impact targeted areas, thereby helping the patient to recover faster with no lingering after effects. The development of HPAPIs has a key driver in the growth of oncology drugs which have shown the maximum demand in the last few years until 2018. The oncology drugs segment has been the leading segment of the global high potency active pharmaceutical ingredient market. This segment is expected to expand at CAGR of 8.3% during the forecast period. The introduction of innovative drugs is the primary growth driver for the oncology segment. Analysts predict that the patent expiry of blockbuster drugs such as Herceptin, Rituxan, and Humira will pave the way for generic drug manufacturers, thereby making these drugs affordable to a wide number of patients. The branded sector constitutes the major share of this market but the patents of this branded sector are expected to expire in the coming few years that will help HPAPI manufacturers (HPAPI CMOs) to cater to multiple clients by producing the generic version of the ingredients in bulk. The other key factor for rapid growth rate is that the majority of blockbuster drugs are nearing patent expiry ad that puts the US government in a position to promote generic drugs to reduce its medical burden. This leads to insurance companies preferring generic drugs over patented drugs for cost effectiveness, while India and China became the hub of HPAPI development through state of the art facilities (HPAPI CMOs) and demand with maximum DMFs with the US FDA. If you have a Highly Potent API, Check all the Attributes of The HPAPI CMO You Need to Consider Given the risks involved in understanding the Chemistry of highly potent active pharmaceutical ingredients (HPAPIs) --- HPAPI Chemistry --- and that during cross-contamination and containment, it is important to consider manufacturing and handling approaches carefully. In fact, because of the exquisite demands of HPAPI manufacturing and complexities of HPAPI Chemistry, many drug developers select a contract development and manufacturing organization (CDMO) partner to make the substance. The discussion below outlines some of the considerations for HPAPI manufacturing and, when appropriate, HPAPI CDMO selection. Check the Salient Features of HPAPI Manufacturing for Selecting HPAPI CMOs With the significant infrastructure and capital investments required for effective HPAPI manufacturing, it is simply not feasible for many of the small and mid-size companies to make this extensive investment. In the suites alone, a top rated HPAPI CMO makes an investment of at least $7 million per year, including its investment in skilled personnel and procedural development. These levels of investment are not possible or prudent for all HPAPI CMOs. Some of the larger pharmaceutical HPAPI manufacturers have chosen to invest in high-potency manufacturing facilities, but even they often outsource manufacturing in the earlier stages of development when the HPAPI Chemistry complications of different types of molecules are minimized so that before potentially transferring production to their own facilities, they are checked for later development stages or for commercial manufacturing. In this way, high-potency development and manufacturing for big pharma is not unlike other outsourcing models in the industry. The manufacture of HPAPIs presents many challenges; however, given the high toxicity, complications of HPAPI chemistry of these compounds and safety is the first and foremost consideration. Manufacturers must have robust engineering controls, risk assessment and risk management processes in place to ensure a safe work environment and prevent cross-contamination. Pharmaceutical companies that outsource HPAPI development and manufacturing look for a CMO that has a proven track record for both safely and effectively managing projects involving highly potent compounds. Such a record includes not only successful commercial production of HPAPIs, but also an excellent audit history, comprehensive documentation and regulatory records. These present significant barriers to entry both for new competing products and CMO suppliers providing these highly-specialized drugs i. e. small molecules or HPAPIs and delivery device combinations. In terms of future growth, China is expected to be the main driver; however, the USA will remain the largest single market ahead of the EU. Isolated HPAPI containment facilities for both drug substances and drug product development and manufacturing should be made available with the following High Containment considerations: • Isolated Class 100,000 suites designed with the most advanced barrier technology, including sophisticated clean-in-place systems • Engineering controls for product containment in segregated suites with dedicated HEPA filtration systems (inbound and exhaust) and individual egress points • Preclinical and clinical trials supply – from 10g to 10’s of kg • Commercial scale manufacturing from grams to 100’s of kg • Handling of Merck Category 4 compounds • Potent solid dose formulation of batch sizes up to 10kg • Facilities FDA and MHRA inspected • Having significant infrastructure and capital investments required for effective HPAPI manufacturing defines the development capacity of a High Potency API Manufacturing unit which is simply not feasible for many of the small and mid-size companies to make this extensive investment. While considering the best HPAPI containment and manufacturing facility, not only should you check the amounts invested in types of molecules that a particular HPAPI CMO produces, but also the equipment installed for proper handling of highly potency APIs and their complex HPAPI chemistry specifications. Various HPAPI CMOs and CDMOs focus on building a workforce of skilled personnel for proper HPAPI containment and handling. The procedural development involves high levels of investment, which may not be possible for many companies and hence are not considered as prudent in all pharmaceutical development companies. Hence HPAPI manufacturing of such high-potency compounds can be outsourced, in fact some of the larger pharmaceutical companies have chosen to invest in high-potency manufacturing facilities, but even they often outsource manufacturing in the earlier stages of development before potentially transferring production of high potency drug substances to their own facilities in later stages or for commercial manufacturing. In this way, high-potency development and manufacturing for big pharma is not unlike other outsourcing models in the industry. The following is a list of questions to ask when selecting an HPAPI CDMO partner: 1. Does the facility or company have experience with HPAPIs? 2. Does it have robust capabilities to prevent cross-contamination? 3. Are contamination-control approaches engineering-based (technology, facility, equipment) or administrative-based (human-centric processes and procedures)? Engineering-controlled processes are far superior. 4. Is the facility overly reliant on personal protection equipment (PPE) for containment and worker safety? 5. Has the facility been specifically designed for HPAPI manufacturing? 6. Can it do small-scale work and scale the product through the various stages of its lifecycle? 7. Has industrial hygiene data been gathered to ensure the controls are actually performing at the expected levels? 8. Does the facility have robust HPAPI regulatory compliance management and quality system programs? The best HPAPI CDMO is the one that can navigate complexity in HPAPI Chemistry, HPAPI Containment and check potency levels for all types of HPAPI Manufacturing needs. Parenteral manufacturing can be a complicated process. Cytotoxics, Antibody-Drug Conjugates (ADCs), highly potent compounds, biologics, and lyophilized products present many challenges and require specialized understanding and expertise. BioPharma Solutions brings longevity of experience in handling complex sterile manufacturing challenges.

Wavelength Pharmaceuticals

Virtual Booth World-Class Developer & Manufacturer of Differentiated APIs// in 50 countries// 198 DMFs Worldwide.

ISRAEL Israel

Contact Supplier

Virtual Booth

CPhI China 2020

Attending

Request a Meeting Now

HPAPI (Highly Potent API) Manufacturing

Supporting Information: Click here to upload a PDF

Link to Supplier Content

wavelength-HPAPI-(Highly-Potent-API)-Manufacturing

- Service Details

Wavelength Pharmaceuticals offers contract manufacturing services for the production of highly potent active pharmaceutical ingredients (HPAPIs) / highly potent drug substances along with steroids and cytotoxic compounds.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Minakem

Virtual Booth CDMO (API & HPAPI)/ Generics/ Security of supply/ Regulatory submission expertise/ Track record performance/ FDA & GMP

FRANCE France

Contact Supplier

Virtual Booth

CPhI Japan 2021

Booth # 1B-66

Request a Meeting Now

High Potency API (HPAPI) Manufacturing

Supporting Information: Click here to upload a PDF

Link to Supplier Content

Minakem-High-Potency-API-(HPAPI)-Manufacturing

- Service Details

Minakem offers a state-of-the-art high containment manufacturing facility to handle high potent APIs (HPAPIs) from early-stage development to scale-up & commercial manufacturing.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Medichem S.A

Virtual Booth Generic APIs,HPAPIs & FDFs/ Chlorhexidine/ CMO for branded & generic products/ 339 DMFs/ 15 CEP/ 866 MAs

SPAIN Spain

Contact Supplier

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

HPAPIs Contract Manufacturing

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

Manufacturing capabilities from our API plant in Malta. We produce Class 4 HPAPIs with OEL down to 40 ng/mÂ³ within cGMP and FDA inspected environments.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

AMRI

Virtual Booth A partner for the pharma and biotech industries to improve patient outcomes & quality of life

United States

Contact Supplier

Virtual Booth

CPhI Japan 2021

1H-9

Request a Meeting Now

Achieve Superior Quality With Less Waste

Supporting Information: Click here to upload a PDF

Link to Supplier Content

AMRI-Achieve-Superior-Quality-With-Less-Waste

- Service Details

Certified by SafeBridge®, AMRI's facilities provide the most advanced technology for the production and safe containment of your compound.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

ScinoPharm Taiwan, Ltd

Virtual Booth A leading process R&D and API Manufacturing service provider to the Global Pharmaceutical Industry.

TAIWAN Taiwan

Contact Supplier

Virtual Booth

CPhI Japan 2021

1C-32

Request a Meeting Now

High Potency Cytotoxics Injectable APIs

Supporting Information: Click here to upload a PDF

Link to Supplier Content

ScinoPharm-High-Potency-Cytotoxics-Injectable-APIs

- Service Details

ScinoPharm provides one-stop-shop service for our existing API customers. The company also adopts Double A (API+ANDA) business model to team up with Pharma companies to apply for ANDA in US/EU and export final drug products globally.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Fermion Oy

Virtual Booth Begin the journey of your innovative API with Fermion.

FINLAND Finland

Contact Supplier

Virtual Booth

Chemspec Europe 2021

Attending

Request a Meeting Now

HPAPI Contract Manufacturing

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

Fermion is a contract manufacturing supplier of APIs, HPAPIs & advanced intermediates with best-in-class facilities and high level of automation. Fermion delivers cost-efficient synthesis, process development & life-cycle management solutions.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Cerbios-Pharma SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

High Potency Active Ingredients Contract Manu...

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

20 years of experience in handling HPAIs according to cGMP, Cerbios is highly qualified in process development and manufacturing of New Chemical Entities with High Potency (High Potency Active Ingredients) characteristics from preclinical to commercial.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

DOTTIKON EXCLUSIVE SYNTHESIS AG

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

State-of-the-art containment concepts

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

To handle active substances, DOTTIKON has state-of-the-art containment concepts on all scales (e.g. closed charging/handling/discharging, full protection suit, monitoring, WIP/CIP cleaning, and cleaning validation). These concepts are applied by highly sk

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Magle Chemoswed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

High Potent Compounds

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

We perform multi-step synthesis and are experts in handling high potent compounds. cGMP standards are applicable also at this scale.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Mac-Chem Products (India) Pvt.Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

Manufacturing of High Potency APIs (HPAPIs)

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

Mac-Chem has state-of-the art cat III & IV containment facility with isolators / glove box technology for manufacturing & handling of highly potent cytotoxic pharmaceutical substances.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Fresenius Kabi Austria

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

AUSTRIA Austria

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

High-Potent

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

high-potent APIs, a special pharma lab was commissioned in 2008 in order to develop and manufacture pharmaceuticals with APIs up to an OEL level of 4.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Dishman Carbogen Amcis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

cGMP Compliant Highly Potent APIs Production

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

The Dishman Group offers unparalleled capability in scale-up, development and commercial manufacture of highly potent APIS and vitamins. All our facilities operate under cGMP.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Ash Stevens, Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

High Potency APIs (HPAPIs)

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

Ash Stevens is a leader in the development and cGMP manufacture of high potency active pharmaceutical ingredients (HPAPIs).

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Arevipharma GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

Handling of Highly Potent Compounds

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

Arevipharma offers three state-of-the-art, multi-purpose plants with a total reactor volume capacity of 150 m3, whichcomply with the cGMP standard and meet almost all customer requirements.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

PROCOS S.p.A.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

High Potency API Manufacturing

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

Procos has established new state-of-the art facility to develop and manufacture High potent APIs and intermediates (HPAPI), with dedicated facilities from R&D to cGMP production: 2 Operation Units for HPAPI small scale manufacturing: up to 5 Kg batch; High containment: down to 30 ng/m3; etc.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Servier

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

HPAPIs Handling – Grams to Tons

Document

- Service Details

Servier brings 60 years of experience in process development, intermediates, APIs and high-potency APIs. Our full cGMP?/?FDA-approved chemistry network includes R&D, production and supply chain expertise with full regulatory support.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Piramal Pharma Solutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

High Potent APIs

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

We manufacture and supply APIs through our sites in North America, Europe, and Asia. Our API facilities have been inspected and approved by several global regulatory bodies including the US FDA, Japan PMDA, UK MHRA and meet the cGMP compliance standards.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

CARBOGEN AMCIS AG

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

Containment Facilities to Produce Highly Pote...

Supporting Information: Click here to upload a PDF

Link to Supplier Content

- Service Details

CARBOGEN AMCIS containment facilities are designed based on a containment concept utilizing barrier isolation technology and Rapid Transfer Ports (RTPs) as well as a strict zone concept with pressure cascades, airlocks and access controls.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Indena

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

Biofit 2020

Participation Not Confirmed

Update your events

CMO for HPAPIs

Document

Link to Supplier Content

- Service Details

Indena is the world’s leading company in the identification, development and production of plant-derived active principles for the pharmaceutical, health-food and personal care industries.

- Directory Listing

Pharma Service: API Manufacturing

Category: High Potency APIs (HPAPIs)

Sub Category: Overview

Find